Holdings
Tri Locum Partners LP
As of Sep 30, 2026, Tri Locum Partners LP reported 16 positions worth US$442M. Largest: Vertex Pharmaceuticals Incorporated, Eli Lilly and Company and Teva Pharmaceutical Industries Limited. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | 133K | US$69.5M | −68,895 | Sep 30, 2026 |
| Eli Lilly and Company | 51,015 | US$59M | −25,517 | Sep 30, 2026 |
| Teva Pharmaceutical Industries Limited | 1.22M | US$48.5M | +477K | Sep 30, 2026 |
| Amneal Pharmaceuticals, Inc. | 2.33M | US$46.9M | new | Sep 30, 2026 |
| DexCom, Inc. | 489K | US$42.2M | −331K | Sep 30, 2026 |
| argenx SE | 30,399 | US$29.1M | −11,197 | Sep 30, 2026 |
| Axsome Therapeutics, Inc. | 143K | US$26.4M | −75,970 | Sep 30, 2026 |
| Johnson & Johnson | 73,559 | US$19.5M | −351K | Sep 30, 2026 |
| Enliven Therapeutics, Inc. | 410K | US$18.8M | −456K | Sep 30, 2026 |
| United Therapeutics Corporation | 33,000 | US$17.9M | −14,026 | Sep 30, 2026 |